Gyeonggawon Bioindustry Headquarters, Transfer of Biotechnology to Private Companies

Gyeonggi Provincial Government

Gyeonggi Province is promoting the transfer of biotechnology to private companies.

The Bio Industry Headquarters of the Gyeonggi Provincial Economic Science Promotion Agency announced on the 2nd that it signed a "Business Agreement for Bio Technology Transfer and Research Cooperation" with three domestic bio companies?LaFle Co., Ltd., SI Bio Co., Ltd., and Nexfarm Korea Co., Ltd.?at the Gyeonggi Bio Center in Suwon Gwanggyo Techno Valley.

This agreement was established to transfer excellent bio technologies developed by the Bio Industry Headquarters of the Economic Science Promotion Agency, supported by Gyeonggi Province, to bio companies within the province and to promote research cooperation for the development of new drugs and health functional products.

The technologies to be transferred include three items: ▲anti-obesity treatment candidate substance for adipocyte remodeling ▲fermented extract of yulmu bran with skin regeneration activation ▲extract of Cheonggasideonggul with blood circulation improvement effects through alleviation of dyslipidemia.

In particular, the anti-obesity treatment candidate substance for adipocyte remodeling converts energy-storing white fat into heat-generating brown fat, consuming excessive energy in the body as heat to regulate body weight. This pharmaceutical material was recognized for its excellence in the world’s top scientific journal in 2016 (Nature Chemical Biology). It was completed in 2018 as part of Gyeonggi Province’s bio new material development project.

This technology, expected to lead the next-generation anti-obesity treatment market by overcoming the side effects of existing appetite suppressants and absorption inhibitors, has been transferred to LaFle Co., Ltd., located in Anyang City.

Na Yuran, head of the LaFle research institute, said, "We are pleased to receive the technology transfer of excellent research results verified over a long period. We will do our best to develop an obesity treatment that enables selective therapy with an innovative strategy differentiated from existing obesity treatments and minimizes side effects."

The fermented extract of yulmu bran with skin regeneration activation, which is a composition developed for skin regeneration effects, will be transferred to SI Bio Co., Ltd., and the extract of Cheonggasideonggul with blood circulation improvement effects through alleviation of dyslipidemia will be transferred to Nexfarm Korea Co., Ltd.

Han Taeseong, head of the Bio Industry Division of Gyeonggi Province, said, "Research and development is the most important for the development of the bio industry, but since it requires a lot of time and cost, it will be difficult to continue research and development by the efforts of individual companies alone. We will continue to strengthen cooperation with domestic companies for the development of the bio industry in Gyeonggi Province."

This content was produced with the assistance of AI translation services.